Anti-Inflammatory Agents for Inpatient Cellulitis
For inpatient cellulitis, systemic corticosteroids (prednisone 40 mg daily for 7 days) can be considered in nondiabetic adults as adjunct therapy, while NSAIDs should generally be avoided due to safety concerns despite some evidence of early benefit. 1
Guideline-Based Recommendations
The 2014 IDSA guidelines provide the primary framework for anti-inflammatory use in cellulitis:
- Corticosteroids: The guidelines suggest systemic corticosteroids (e.g., prednisone 40 mg daily for 7 days) could be considered in nondiabetic adult patients with cellulitis, though this is a weak recommendation with moderate-quality evidence 1
- Key exclusion: This recommendation specifically excludes diabetic patients, who should not receive corticosteroids
NSAIDs: Mixed Evidence with Safety Concerns
The evidence on NSAIDs presents a concerning picture:
Potential early benefit:
- A 2024 meta-analysis found oral NSAIDs as adjunct therapy may improve early clinical response at day 3 (RR 1.81,95% CI 1.42-2.31), but this benefit was not sustained beyond 4-5 days 2
- One small 2005 study showed 82.8% of patients had regression of inflammation within 1-2 days with ibuprofen versus only 9.1% without 3
However, significant safety concerns exist:
- A 2017 double-blind RCT found no significant benefit of ibuprofen 400 mg three times daily versus placebo in uncomplicated cellulitis 4
- Critical warning: A 2015 study of cervicofacial cellulitis found 80% of severe cases had taken NSAIDs, including two fatal cases with mediastinal extension. The authors concluded NSAIDs should be used "with caution if at all" in infections 5
Clinical Algorithm for Anti-Inflammatory Use
Step 1: Assess diabetes status
- Diabetic → Do NOT use corticosteroids
- Nondiabetic → Proceed to Step 2
Step 2: Consider corticosteroids for nondiabetic inpatients
- Prednisone 40 mg daily for 7 days as adjunct to appropriate antibiotics
- Monitor for typical steroid side effects
Step 3: Avoid NSAIDs in most cases
- The risk-benefit ratio does not favor routine NSAID use
- Any early benefit (days 1-3) is not sustained
- Serious complications including necrotizing infection have been reported
Important Caveats
Primary treatment remains antibiotics: Anti-inflammatories are only adjunctive therapy. The mainstay is appropriate antibiotic coverage (typically β-lactams for streptococci in uncomplicated cases) 1
Supportive measures are essential: Elevation of the affected extremity and treatment of predisposing factors (tinea pedis, venous insufficiency) should always be implemented 1
The corticosteroid recommendation is weak: Based on limited evidence, clinicians should weigh individual patient factors carefully. The benefit appears modest and the evidence base is not robust 1, 2
NSAIDs may mask progression: The concern is that anti-inflammatory effects could obscure worsening infection, potentially delaying recognition of necrotizing fasciitis or other severe complications 5